chloroquine has been researched along with Glycogen Storage Disease Type I in 4 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Glycogen Storage Disease Type I: An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The primary outcome was the incidence of severe haemolysis or other serious adverse events (SAEs)." | 2.71 | Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. ( Burhenne, J; Coulibaly, B; Jahn, A; Kouyaté, B; Mandi, G; Mansmann, U; Meissner, PE; Mikus, G; Müller, O; Rengelshausen, J; Riedel, KD; Sanon, M; Schiek, W; Schirmer, H; Tapsoba, T; Walter-Sack, I; Witte, S, 2005) |
| "Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952." | 2.47 | Primaquine in vivax malaria: an update and review on management issues. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernando, D | 1 |
| Rodrigo, C | 1 |
| Rajapakse, S | 1 |
| Meissner, PE | 1 |
| Mandi, G | 1 |
| Witte, S | 1 |
| Coulibaly, B | 1 |
| Mansmann, U | 1 |
| Rengelshausen, J | 1 |
| Schiek, W | 1 |
| Jahn, A | 1 |
| Sanon, M | 1 |
| Tapsoba, T | 1 |
| Walter-Sack, I | 1 |
| Mikus, G | 1 |
| Burhenne, J | 1 |
| Riedel, KD | 1 |
| Schirmer, H | 1 |
| Kouyaté, B | 1 |
| Müller, O | 1 |
| Rebholz, CE | 1 |
| Michel, AJ | 1 |
| Maselli, DA | 1 |
| Saipphudin, K | 1 |
| Wyss, K | 1 |
| Handa, R | 1 |
| Wig, N | 1 |
| Aggarwal, P | 1 |
| Suresh, V | 1 |
| Biswas, A | 1 |
| Wali, JP | 1 |
1 review available for chloroquine and Glycogen Storage Disease Type I
| Article | Year |
|---|---|
Primaquine in vivax malaria: an update and review on management issues.
Topics: Aminoquinolines; Antimalarials; Artemisinins; Chloroquine; Clinical Trials as Topic; Drug Resistance | 2011 |
1 trial available for chloroquine and Glycogen Storage Disease Type I
| Article | Year |
|---|---|
Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841].
Topics: Burkina Faso; Child, Preschool; Chloroquine; Drug Therapy, Combination; Glycogen Storage Disease Typ | 2005 |
2 other studies available for chloroquine and Glycogen Storage Disease Type I
| Article | Year |
|---|---|
Frequency of malaria and glucose-6-phosphate dehydrogenase deficiency in Tajikistan.
Topics: Adult; Chloroquine; Glycogen Storage Disease Type I; Hemolysis; Humans; Malaria; Malaria, Vivax; Mal | 2006 |
Halofantrine in G-6 PD deficiency.
Topics: Aged; Antimalarials; Chloroquine; Glycogen Storage Disease Type I; Hemolysis; Humans; Malaria, Falci | 1997 |